Two Sigma Advisers LP Purchases 48,100 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Two Sigma Advisers LP grew its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 7.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 669,352 shares of the company's stock after purchasing an additional 48,100 shares during the period. Two Sigma Advisers LP owned approximately 0.78% of Syndax Pharmaceuticals worth $12,885,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the business. Sphera Funds Management LTD. boosted its stake in Syndax Pharmaceuticals by 25.9% during the third quarter. Sphera Funds Management LTD. now owns 1,034,846 shares of the company's stock worth $19,921,000 after acquiring an additional 212,799 shares in the last quarter. State Street Corp boosted its stake in Syndax Pharmaceuticals by 4.1% during the third quarter. State Street Corp now owns 3,770,826 shares of the company's stock worth $72,588,000 after acquiring an additional 148,491 shares in the last quarter. Stifel Financial Corp bought a new position in shares of Syndax Pharmaceuticals in the third quarter worth approximately $327,000. PFM Health Sciences LP lifted its stake in shares of Syndax Pharmaceuticals by 9.4% in the third quarter. PFM Health Sciences LP now owns 423,910 shares of the company's stock worth $8,160,000 after buying an additional 36,553 shares in the last quarter. Finally, Eventide Asset Management LLC bought a new position in shares of Syndax Pharmaceuticals in the third quarter worth approximately $15,150,000.

Syndax Pharmaceuticals Stock Down 4.0 %

SNDX traded down $0.62 during trading on Tuesday, hitting $14.94. The company's stock had a trading volume of 1,867,521 shares, compared to its average volume of 1,179,454. Syndax Pharmaceuticals, Inc. has a one year low of $14.57 and a one year high of $25.34. The firm has a market cap of $1.28 billion, a PE ratio of -4.29 and a beta of 0.86. The business's 50 day simple moving average is $18.22 and its 200-day simple moving average is $19.62.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.98) earnings per share for the quarter, topping the consensus estimate of ($1.13) by $0.15. The business had revenue of $12.50 million during the quarter, compared to the consensus estimate of $9.16 million. During the same quarter in the previous year, the business posted ($0.73) earnings per share. Equities research analysts expect that Syndax Pharmaceuticals, Inc. will post -2.39 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Barclays upped their target price on shares of Syndax Pharmaceuticals from $32.00 to $33.00 and gave the stock an "overweight" rating in a research note on Thursday, August 15th. The Goldman Sachs Group upped their target price on shares of Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a "buy" rating in a research note on Thursday, November 7th. Citigroup upped their target price on shares of Syndax Pharmaceuticals from $37.00 to $45.00 and gave the stock a "buy" rating in a research note on Tuesday, November 19th. UBS Group assumed coverage on shares of Syndax Pharmaceuticals in a research note on Thursday, October 24th. They issued a "buy" rating and a $37.00 target price on the stock. Finally, Stifel Nicolaus upped their target price on shares of Syndax Pharmaceuticals from $40.00 to $41.00 and gave the stock a "buy" rating in a research note on Monday, October 14th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have given a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $37.64.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).